Valuation: Evotec SE

Market Cap 449M 503M 418M 380M 715M 47.68B 728M 5.02B 1.96B 24.88B 1.89B 1.85B 79.61B P/E 2026 *
-1.98x
P/E 2027 * -5.88x
Enterprise Value 592M 663M 550M 501M 942M 62.84B 959M 6.61B 2.59B 32.79B 2.49B 2.44B 105B EV / Sales 2026 *
0.99x
EV / Sales 2027 * 0.85x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week-9.55%
Current month-16.96%
1 month-12.88%
3 months-29.35%
6 months-55.76%
Current year-53.90%
1 week 1.33
Extreme 1.33
1.48
1 month 1.33
Extreme 1.33
1.75
Current year 1.33
Extreme 1.33
3.87
1 year 1.33
Extreme 1.33
4.27
3 years 1.33
Extreme 1.33
12
5 years 1.33
Extreme 1.33
26.57
10 years 1.33
Extreme 1.33
26.57
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%-9.55% - - 503M
+0.21%-4.63%+55.34%+71.32% 68.98B
+1.66%+7.51%+8.12%+60.04% 53.15B
+3.14%+7.17%+12.48%+44.42% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
+1.73%-8.08%+35.02%+1.02% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +1.71%+1.56%+49.19%+98.55% 42.19B
Weighted average by Cap. +1.91%+2.33%+51.45%+103.65%

Financials

2026 *2027 *
Net sales 599M 671M 557M 506M 952M 63.54B 970M 6.69B 2.62B 33.15B 2.52B 2.46B 106B 721M 808M 670M 610M 1.15B 76.55B 1.17B 8.05B 3.15B 39.94B 3.03B 2.97B 128B
Net income -222M -249M -206M -188M -353M -23.56B -359M -2.48B -970M -12.29B -933M -914M -39.33B -48.25M -54.06M -44.84M -40.79M -76.74M -5.12B -78.13M -539M -211M -2.67B -203M -199M -8.55B
Net Debt 143M 160M 133M 121M 227M 15.16B 231M 1.59B 624M 7.91B 601M 588M 25.31B 162M 182M 151M 137M 258M 17.21B 263M 1.81B 708M 8.98B 682M 667M 28.73B
Projected Income Statement - Annual - Evotec SE
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Date Price Change Volume
15/10/26 $1.420 -0.35% 123,977
14/10/26 $1.425 +5.95% 158,371
13/10/26 $1.345 -1.82% 113,956
12/10/26 $1.370 -10.46% 182,620
09/10/26 $1.530 -2.55% 40,005
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Evotec SE
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
2.528EUR
Average target price
4.443EUR
Spread / Average Target
+75.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Evotec SE